(GP) as a marker for variant viruses with the CTL-P+ phenotype. An RNA PCR assay that detects the variant GP sequence and thus allows kinetic studies of the selection of the Leu at position 260 was developed. We found that although CTL-P+ viruses are known to be lymphotropic, mature T and B cells were not required for the generation and selection of the Leu at GP amino acid 260. Kinetically, in mice infected at birth with LCMV ARM, as early as 3 weeks postinfection the Phe-to-Leu change was found in virus in the serum. By 5 weeks, viral nucleic acid obtained from peritoneal macrophages, spleen, lymph nodes, and liver showed the Phe-to-Leu change. At 2 months postinfection, the Leu change was detected in virus from the thymus, heart, lung, and kidney. By contrast, virus replicating in the central nervous system showed only minimal levels of the Leu change by 4 months and as long as 1 year postinfection. In vitro studies showed that the parental LCMV ARM CTL+ P-virus replicates more efficiently and outcompetes CTL-P+ virus in a cultured neuronal cell line, indicating that differential growth properties in neurons are likely the basis for the selection of the parental virus over the CTL-P+ variant in the brain.
Lymphocytic choriomeningitis virus (LCMV) is an arenavirus that is a natural pathogen of mice. The outcome of infection with this virus is dependent on the virus isolate, dose, and route of inoculation and the age and strain of the mice. Intraperitoneal (i.p.) or intravenous inoculation of up to 2 x 106 PFU of LCMV strain Armstrong (ARM) into adult mice causes an acute infection which is cleared by 7 to 10 days postinfection (7, 19) . Viral clearance is mediated by a virus specific CD8+ cytotoxic T-lymphocyte (CTL) response (9, 11, 25 ; reviewed in references 7, 24, and 36), and because of this host response, LCMV ARM is referred to as a CTL+ P-(CTL-positive, persistence-negative) virus. By contrast, mice infected with LCMV within 24 h of birth are unable to mount a protective CTL response because of thymic deletion of LCMV-reactive T cells and thus become persistently infected for life (7, 18, 24) . By in situ hybridization analysis, viral nucleic acid is detected throughout the body, and infectious virus can be isolated from many different tissues (30) . These mice, while not mounting anti-LCMV CTL responses, are able to mount effective CTL responses to other RNA and DNA viruses (20, 34) .
Several viral isolates derived from adult mice which were persistently infected since birth by LCMV ARM show differences in their biological properties compared with the parental virus (2, 3) . These variants, the prototype of which is the clone 13 isolate, are not cleared after intravenous inoculation of 2 x 106 PFU into adult mice but are able to establish a persistent infection (referred to as CTL-P+ viruses). This is due to the fact that the CTL response generated following infection with these virus variants is abortive and is insufficient to clear the infection. Additionally, not only is the LCMV-specific CTL activity suppressed, but mice persistently infected with clone 13 exhibit a generalized immunodeficiency and when subsequently infected by other pathogens mount impaired immune responses (4, 20, 34, 35) .
The molecular basis by which clone 13 induces a persistent infection has been mapped. LCMV has an ambisense, bisegmented RNA genome that encodes at least four proteins. The small (S) segment encodes the viral nucleoprotein (NP) and the glycoprotein precursor (GP-C), which is cleaved to give GP-1 and GP-2. The large (L) segment encodes the putative viral polymerase (L gene) and a small zinc-binding protein, the Z protein. When the complete RNA sequences of the parental ARM strain and the variant clone 13 were compared, five nucleotide changes were found, resulting in only two amino acid coding changes: amino acid 260 in the viral GP (phenylalanine [Phe] to leucine [Leu] ) and amino acid 1079 in the putative polymerase (lysine to glutamate) (22, 27, 28) . Studies with reassortant viruses suggested that the nucleotide changes on both the S and L segments are important for the persistence phenotype (21, 22) . Examination of more than 20 other CTL-P+ variants of ARM that were also isolated from lymphoid tissue and caused persistent infection of adult mice showed that the Leu at amino acid 260 of the GP is associated with the persistence phenotype and therefore is a good marker for variants of LCMV ARM that are able to cause persistent infection (1, 27 CTL+ P-and CTL-P+ growth in GT1-7 and PC12 cells and their competition in GT1-7 cells. The mouse GT1-7 cell line (23) was grown in Dulbecco's modified Eagle's medium containing penicillin, streptomycin, 1% glutamine, 6% heatinactivated fetal bovine serum, and 6% heat-inactivated horse serum. These cells were derived from a hypothalamic neuronal tumor and retain neuronal characteristics when grown in tissue culture. PC12 cells were derived from a rat pheochromocytoma clone and have been used extensively as a model of neuronal differentiation (12, 15) . PC12 cells were grown in supplemented RPMI 1640 medium as reported previously (15) . BHK cells were grown in Dulbecco's modified Eagle's medium supplemented with penicillin, streptomycin, 1% glutamine, 0.7% glucose, 5% 2x tryptose phosphate broth, 3.5% heat-inactivated fetal bovine serum, and 3.5% heat-inactivated calf serum. GT1-7, PC12, and BHK cells were infected with ARM or clone 13 at a multiplicity of infection (MOI) of 3. At 0, 24, 48, and 72 h postinfection, the supernatants were collected and viral titers were determined by plaque assay on Vero cells as described previously (14) . In competition experiments, GT1-7 cells were infected with ARM or clone 13 alone at an MOI of 3 or with a 1:5 mixture of ARM and clone 13 with ARM at an MOI of 1. Supernatants were collected at 72 h postinfection, frozen at -70°C, and then used to infect more GT1-7 cells. In this manner, the viruses were passaged six times through the GT1-7 cells. At each passage, the cells were harvested, and RNA was extracted and analyzed by the RNA PCR-MnlI technique described above.
RESULTS
The nucleotide diference at position 855 in LCMV ARM and clone 13 can be distinguished by RNA PCR. Examination of the LCMV GP cDNA nucleotide sequence coding for the Phe-to-Leu amino acid 260 change in clone 13 revealed that the U-to-C change at nucleotide 855 creates a cleavage site for the restriction enzyme MnlI in the cDNA of clone 13 (Fig. 1A) . This finding was used to design an RNA PCR strategy that would enable us to detect the presence of the Leu at amino acid 260 in total cellular RNA extracted from infected cells or tissue (Fig. 1B) . RNA is first transcribed into cDNA by using Moloney murine leukemia virus reverse transcriptase and random hexamers as primers. The primers chosen for PCR hybridize near amino acid 260 of the viral GP and upon amplification using Taq polymerase generate a 362-bp DNA product. MnlI digestion of the clone 13 PCR product results in cleavage into two DNA fragments of 202 and 160 bp, whereas MnlI does not recognize the DNA sequence of the ARM PCR product (Fig. 1B) . To test this method, ARM and clone 13 were grown in BHK cells, and total cellular RNA was purified and analyzed by the RNA PCR-MnlI technique (Fig. 2) . The PCR product obtained from ARM-infected cells was not cleaved with MnlI, whereas MnlI completely digested the clone 13 PCR product into two fragments of 202 and 160 bp. RNA PCR-MnlI cleavage of a 1:1 mixture of ARM and clone 13 RNA resulted in partial digestion of the PCR product by MnlI (Fig. 2) in Fig. 3 . Five-week-old mice infected at birth with ARM showed an MnlI-cleavable PCR product in RNA from serum, activated peritoneal macrophages, lymph nodes, spleen, and liver (Fig. 3A) ; in 11-week-old mice, the change was also found in the thymus, heart, and lung and at minimal levels in kidney (Fig. 3B) . The kinetics of the GP amino acid 260 change are summarized in Fig. 4 . At all time points and in all cell types tested, viral RNA sequences were always detected by RNA PCR, but the amount cleavable by MnlI varied with age and tissue type. The Leu at GP amino acid 260 was detected first at 3 weeks in serum samples and by 5 weeks appeared in thioglycolate-elicited peritoneal macrophages, lymph nodes, spleen, and liver. By 2 months, it was detected in the thymus, heart, and lung, and at a low level in the kidney. By 4 months, very low levels of the GP Leu-260 change were detected in brain tissue, and even after 1 year only minimal amounts of the Leu change were noted, despite the high proportion of variant virus containing this change found in various other organs and serum (data not shown). Because of the redundancy of the genetic code, other mutations in the parental ARM virus sequence could result in a Leu at amino acid 260 in the GP that would not result in the generation of an MnlI site. One of these, UUC to UUA, would be detectable by cleavage of the RNA PCR product with the restriction enzyme MseI; however, such analysis of tissues at various time points never detected the presence of this mutation. In addition, sequence analysis of more than 20 other CTL-P+ variants (1, 28) detected only the U-to-C change at nucleotide 855 that produces the MnlI restriction site analyzed in this report.
Where does the GP amino acid 260 change first appear? The leucine at GP amino acid 260 was detected early in cells and tissues of the immune system (macrophages, spleen, lymph nodes), suggesting that this mutation may give a growth advantage to the virus in one or more cell types of the immune system. To address whether the variant is first selected in lymphocytes in the spleen, CD4+, CD8+, and B220 cell populations from the spleen were isolated by fluorescenceactivated cell sorting and analyzed by RNA PCR-MnlI digestion. In these isolated populations (>97% pure), the Leu at GP amino acid 260 was not detected until 2 months postinfection, compared with its presence in intact spleens at 5 weeks postinfection, suggesting that the variant may first be found in cells other than lymphocytes in the spleen (data not shown). To show that mature T and/or B cells are not necessary to obtain the GP amino acid 260 change, adult athymic and neonatal SCID mice were infected with ARM and then examined for the selection of the GP variant. Since CD8+ cells are required for viral clearance (9, 11, 25, 36) , athymic mice infected as adults become persistently infected with ARM. At various times postinfection, the athymic and SCID mice were sacrificed and RNA was isolated from peritoneal macrophages, lymph nodes, and spleen. At 6 weeks postinfection, viral RNA PCR products from athymic and SCID peritoneal macrophages were cleaved by MnlI (also seen in lymph nodes and spleen; data not shown), in contrast to the ARM virus used to inoculate the mice (Fig. 5) . This finding indicates that the GP amino acid 260 variant can be initially selected in a cell type other than mature lymphocytes.
Differential growth abilities of the parental CTL+ P-virus and the CTL-P+ variant in neuronal cells. In mice persistently infected with LCMV since birth, virus within the brain is harbored in neurons (16, 26) . Since minimal amounts of virus with the GP Phe-260-to-Leu change were found in the brain, the replication of ARM (CTL+ P-) and the replication of clone 13 (CTL-P+) were compared in two neuronal cell lines. Fig. 7 , when the GT1-7 cells were initially infected with a 1:5 mixture of ARM and clone 13, by the fourth passage only minimal amounts of PCR product were cleaved by MnlI, and by the sixth passage no cleavage of the PCR product was detected. This finding indicates that the ARM virus had successfully outcompeted clone 13 for growth in the GT1-7 cells. After six sequential passages of ARM in GT1-7 cells, the Phe-260-to-Leu change in the GP was not detected (Fig. 7) . We noted, however, that when clone 13 was sequentially passaged in GT1-7 cells, by the sixth passage a minor amount of RNA PCR product was no longer cleaved by MnlI, indicating that a nucleotide change in the codon for GP amino acid 260 had occurred in this viral population. Since the proportion of virus containing this change in the sixth passage was very minor, it is not likely that this accounts for the ability of ARM to outcompete clone 13 for growth in the GT1-7 cells.
DISCUSSION
In this report we have examined the kinetics of the selection of a viral variant containing an amino acid change associated with viral persistence and immunosuppression. This was made possible by an RNA PCR-MnlI digestion technique that allowed us to detect a single amino acid change in the parental virus, LCMV ARM (CTL' P-), in infected tissues. We found that there is a strong selection for the Phe-to-Leu change at amino acid 260 of the viral GP in most tissues analyzed with 6nmoI+ + + + + + + + (+) ( (5, 10) .
LCMV is an excellent model with which to study the generation and selection of viral variants. LCMV productively infects most tissues (7, 19) , and organ-specific variants which alter host control of the virus have been isolated and characterized (2, 3) . Analysis of variants isolated from the spleens of mice infected at birth with LCMV ARM showed that a Phe-to-Leu amino acid change at position 260 of the viral GP was associated with the ability to cause persistent infection in adult mice (1, 22, 27, 28 (Fig. 4) . By 2 months postinfection, significant amounts of variant virus with the Leu-260 change were detected in heart and lung, with a low level in the kidney. Interestingly, the brain was markedly resistant to the Leu mutation at position 260 of the GP even after 1 year of infection. The discordance of brain with other tissues (lymphoid, liver, heart, lung) and differences in the kinetics of the GP amino acid 260 change in lymphoid tissues compared with heart and lung indicate that it is improbable that blood contamination within tissues accounts for the detection of the GP amino acid 260 change but rather that there is a selective growth advantage for the GP amino acid 260 variant virus in a selected cell type(s) within every tissue in which the variant was detected.
This hypothesis of specific cell selection was tested and confirmed with studies of the growth of CTL+ P-and CTL-P+ viruses in the neuronal GT1-7 and PC12 cell lines. In persistently infected mice, LCMV replicates almost exclusively in neurons, regardless of whether CTL+ P-or CTL-P+ virus is used to initiate infection (16, 26, 34a) . Analysis of viral RNA from the brains of mice persistently infected with ARM during the course of infection from its onset at birth to 1 year revealed minimal amounts of viral nucleic acid coding for the Leu at amino acid 260 of the GP (Fig. 4) . Interestingly, in both the GT1-7 and PC12 neuronal cell lines, ARM multiplied more efficiently than did the clone 13 variant that contains Leu at amino acid 260 of the GP (Fig. 6) . Further, ARM outcompeted clone 13 for growth during serial undiluted passages in GT1-7 cells, even when the initial infection was done with a 5:1 ratio of clone 13 to ARM. By contrast to neurons in the brain, the variant containing a Leu at amino acid 260 shows a selective growth advantage in immune tissues (Fig. 4) (1, 17) . Biologically, the enhanced growth of CTL-P+ virus in cells of the immune system over that observed with CTL+ P-virus parallels the observation that adult mice infected with CTL+ P-parental ARM generate a CTL response that clears the viral infection, whereas the CTL response in adult mice infected with CTL-P+ clone 13 
